10x Genomics (TXG) Tops Q2 EPS by 16c

10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.10), $0.16 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $115.8 million versus the consensus estimate of $112.85 million.

GUIDANCE:

10x Genomics sees FY2021 revenue of $480-500 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Bernstein SocGen on UnitedHealth Group (UNH): 'Expecting a strong 2Q driven by MA and potential for guidance raise'
• Doximity downgraded by BofA on AI investment concerns, margin pressure